ArticlePloS one2014
Clinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial.Arthritis research & therapy · 2016Trial
- Assessing the psychometric properties of the World Health Organization -five well-being index (WHO-5) in Filipino samples amid the COVID-19 pandemic.BMC psychology · 2024Article
- Emotional intelligence: a novel predictor of quality of life in patients with systemic sclerosis.Rheumatology international · 2024Article
- Assessing hand and global disability in a cohort of Algerian patients with systemic sclerosis: Construct validities of the Arab Hand Function Index and the Arabic Health Assessment Questionnaire.Journal of scleroderma and related disorders · 2024Article
- Perception of aesthetic impairment in patients with systemic sclerosis determined using a semi-quantitative scale and its association with disease characteristics.Journal of scleroderma and related disorders · 2024Article
- Determinants of Depressive Symptoms, Quality of Life, Subjective Health Status and Physical Limitation in Patients with Systemic Sclerosis.Acta dermato-venereologica · 2023Article
- Perceived Cognitive Function in People With Systemic Sclerosis: Associations With Symptoms and Daily Life Functioning.Arthritis care & research · 2023Article
- Low cognitive functioning and depressive symptoms in patients with rheumatoid arthritis and systemic sclerosis: a clinical study.BMC psychiatry · 2023Article
- Differences in Disability Perception in Systemic Sclerosis: A Mirror Survey of Patients and Health Care Providers.Journal of clinical medicine · 2023Article
- The effect of a self-management program on the quality of life of patients with scleroderma.Journal of education and health promotion · 2023Article
- Clinically Recognized Depression and Mental Health Treatment in a Single Center Cohort of Patients with Systemic Sclerosis.International journal of rheumatology · 2023Article
- Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS).Journal of scleroderma and related disorders · 2021Article
- Pain chronification and the important role of non-disease-specific symptoms in patients with systemic sclerosis.Arthritis research & therapy · 2021Article
- The Relationship Between Autonomic Dysfunction of the Gastrointestinal Tract and Emotional Distress in Patients With Systemic Sclerosis.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2021Article
- Validity and reliability of the Patient Health Questionnaire-8 in Swedish for individuals with systemic sclerosis.Rheumatology international · 2020Article
- A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study.Experimental and therapeutic medicine · 2020Article
- Patient perception of disease burden in diffuse cutaneous systemic sclerosis.Journal of scleroderma and related disorders · 2020Article
- Psychological and self-management support for people with vasculitis or connective tissue diseases: UK health professionals' perspectives.Rheumatology advances in practice · 2020Article
- Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis.Archives of rheumatology · 2019Article
- Association between cortisol levels and pain threshold in systemic sclerosis and major depression.Rheumatology international · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify clinical, functional and health-related quality of life (HRQoL) correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis (SSc).
methodsThree-hundred-and-eighty-one patients fulfilling the American College of Rheumatology and/or the Leroy and Medsger criteria for SSc were assessed for visceral involvement, disability and HRQoL (assessed by SF-36). Clinically significant symptoms of anxiety and depression were evaluated with the Hospital Anxiety Depression Scale (HAD) (defined cut-off≥8).
results9.2% the patients had limited SSc, 50.5% limited cutaneous SSc (lcSSc), and 40.3% diffuse cutaneous SSc (dcSSc). Overall, 40.4% and 58.8% of the patients had clinically significant symptoms of depression and anxiety, respectively. Compared to patients without clinically significant symptoms of depression, patients with clinically significant symptoms of depression had poorer health status, HRQoL mental and physical component, and greater global disability, hand disability and aesthetic impairment. Compared to patients without clinically significant symptoms of anxiety, patients with clinically significant symptoms of anxiety had poorer SF-36 mental and physical component scores. On multivariable analysis, excluding mental component score of SF-36, variables independently associated with clinically significant symptoms of depression and anxiety were global disability and physical component of SF-36, plus female gender for clinically significant symptoms of anxiety only. Remarkably, patients with and without clinically significant psychiatric symptoms were comparable for all disease-related clinical features assessed.
conclusionHigh levels of clinically significant symptoms of anxiety and depression are observed among SSc patients. Clinically significant psychiatric symptoms are rather associated with increased disability and altered HRQoL, than with disease-specific organ manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.